Psychomotor Stimulation by Dopamine D1-Like But Not D2-Like Agonists in Most Mouse Strains

Experimental and Clinical Psychopharmacology

Volumn 19, Issue 5, 2011, Pages 342-360

  Thomsen, Morgane ^a   Ralph, Rebecca J ^a   Caine, S Barak ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Direct dopamine agonists; Locomotor activity; Mouse strains; Quinelorane; R 6 Br APB

Indexed keywords

DIAZEPAM; DOPAMINE 1 RECEPTOR STIMULATING AGENT; QUINELORANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; EXPERIMENTAL DESIGN; FEMALE; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PSYCHOMOTOR ACTIVITY; RAT; SEIZURE; SPRAGUE DAWLEY RAT; STIMULATION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE AGONISTS; DRUG EVALUATION, PRECLINICAL; FEMALE; HYPERKINESIS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, INBRED STRAINS; MODELS, ANIMAL; MOTOR ACTIVITY; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS; SPECIES SPECIFICITY;

EID: 80054113970     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/a0024053     Document Type: Article

References (59)

1. Bergman J., Kamien J.B., Spealman R.D. Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behavioural Pharmacology 1990, 1(4):355-363.
2. Boehme R.E., Ciaranello R.D. Dopamine receptor binding in inbred mice: Strain differences in mesolimbic and nigrostriatal dopamine binding sites. Proceedings of the National Academy of Sciences of the United States of America 1981, 78(5):3255-3259.
3. Boulay D., Depoortere R., Perrault G., Borrelli E., Sanger D.J. Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists. Neuropharmacology 1999, 38(9):1389-1396.
4. Boulay D., Depoortere R., Rostene W., Perrault G., Sanger D.J. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology 1999, 38(4):555-565.
5. Bristow L.J., Cook G.P., Gay J.C., Kulagowski J.J., Landon L., Murray F., Hutson P.H. The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology 1996, 35(3):285-294.
6. Caine S.B., Koob G.F. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993, 260(5115):1814-1816.
7. Caine S.B., Negus S.S., Mello N.K., Bergman J. Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. Journal of Pharmacology and Experimental Therapeutics 1999, 291(1):353-360.
8. Caine S.B., Negus S.S., Mello N.K., Patel S., Bristow L., Kulagowski J., Borrelli E. Role of dopamine D2-like receptors in cocaine self-administration: Studies with D2 receptor mutant mice and novel D2 receptor antagonists. Journal of Neuroscience 2002, 22(7):2977-2988.
9. Caine S.B., Thomsen M., Gabriel K.I., Berkowitz J.S., Gold L.H., Koob G.F., Xu M. Lack of self-administration of cocaine in dopamine D1 receptor knock-out mice. Journal of Neuroscience 2007, 27(48):13140-13150.
10. Campbell-Meiklejohn, D., Wakeley, J., Herbert, V., Cook, J., Scollo, P., Ray, M. K., ... Rogers, R. D. Serotonin and dopamine play complementary roles in gambling to recover losses. Neuropsychopharmacology, 36(2), 402-410.
11. Centonze D., Usiello A., Gubellini P., Pisani A., Borrelli E., Bernardi G., Calabresi P. Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology 2002, 27(5):723-726.
12. Chang W.L., Geyer M.A., Buell M.R., Weber M., Swerdlow N.R. The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice. Behavioural Pharmacology 2010, 21(2):135-143.
13. Collins G.T., Truccone A., Haji-Abdi F., Newman A.H., Grundt P., Rice K.C., Woods J.H. Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. Journal of Pharmacology and Experimental Therapeutics 2009, 329(1):210-217.
14. Cook C.D., Beardsley P.M. The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice. Pharmacology, Biochemistry and Behavior 2003, 75(2):363-371.
15. Cook C.D., Newman J.L., Winfree J.C., Beardsley P.M. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice. Pharmacology, Biochemistry and Behavior 2004, 77(2):309-318.
16. Deroche V., Caine S.B., Heyser C.J., Polis I., Koob G.F., Gold L.H. Differences in the liability to self-administer intravenous cocaine between C57BL/6 x SJL and BALB/cByJ mice. Pharmacology, Biochemistry and Behavior 1997, 57(3):429-440.
17. Desai R.I., Terry P., Katz J.L. A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice. Pharmacology, Biochemistry and Behavior 2005, 81(4):843-848.
18. Doherty J.M., Masten V.L., Powell S.B., Ralph R.J., Klamer D., Low M.J., Geyer M.A. Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology 2008, 33(11):2648-2656.
19. Eilam D., Szechtman H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. European Journal of Pharmacology 1989, 161(2-3):151-157.
20. Frances H., Smirnova M., Leyris A., Aymard N., Bourre J. Influence of social isolation and 6-OHDA lesion on the effects of quinelorane. Pharmacology, Biochemistry and Behavior 2001, 69(1-2):143-149.
21. Gerlai R. Gene-targeting studies of mammalian behavior: Is it the mutation or the background genotype?. Trends in Neurosciences 1996, 19(5):177-181.
22. Geter-Douglass B., Katz J.L., Alling K., Acri J.B., Witkin J.M. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists. Journal of Pharmacology and Experimental Therapeutics 1997, 283(1):7-15.
23. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl) 2001, 156(2-3):117-154.
24. Gill K.J., Boyle A.E. Confirmation of quantitative trait loci for cocaine-induced activation in the AcB/BcA series of recombinant congenic strains. Pharmacogenetics 2003, 13(6):329-338.
25. Grech D.M., Spealman R.D., Bergman J. Self-administration of D1 receptor agonists by squirrel monkeys. Psychopharmacology (Berl) 1996, 125(2):97-104.
26. Halberda J.P., Middaugh L.D., Gard B.E., Jackson B.P. DAD1- and DAD2-like agonist effects on motor activity of C57 mice: Differences compared to rats. Synapse 1997, 26(1):81-92.
27. Helmeste D.M., Seeman P. Amphetamine-induced hypolocomotion in mice with more brain D2 dopamine receptors. Psychiatry Research 1982, 7(3):351-359.
28. Iversen S.D., Iversen L.L. Dopamine: 50 years in perspective. Trends in Neurosciences 2007, 30(5):188-193.
29. Jackson D.M., Westlind-Danielsson A. Dopamine receptors: Molecular biology, biochemistry and behavioural aspects. Pharmacology and Therapeutics 1994, 64(2):291-370.
30. Kelly M.A., Rubinstein M., Phillips T.J., Lessov C.N., Burkhart-Kasch S., Zhang G., Low M.J. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. Journal of Neuroscience 1998, 18(9):3470-3479.
31. Lathe R. Mice, gene targeting and behaviour: More than just genetic background. Trends in Neurosciences 1996, 19(5):183-186. discussion 188-189.
32. Li S.M., Collins G.T., Paul N.M., Grundt P., Newman A.H., Xu M., Katz J.L. Yawning and locomotor behavior induced by dopamine receptor agonists in mice and rats. Behavioural Pharmacology 2010, 21(3):171-181.
33. Lindgren N., Usiello A., Goiny M., Haycock J., Erbs E., Greengard P., Fisone G. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(7):4305-4309.
34. Manzione B.M., Bernstein J.R., Franklin R.B. Observations on the absorption, distribution, metabolism, and excretion of the dopamine (D2) agonist, quinelorane, in rats, mice, dogs, and monkeys. Drug Metabolism and Disposition 1991, 19(1):54-60.
35. Martelle J.L., Claytor R., Ross J.T., Reboussin B.A., Newman A.H., Nader M.A. Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxami de] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzami de], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 2007, 321(2):573-582.
36. Mhyre T.R., Chesler E.J., Thiruchelvam M., Lungu C., Cory-Slechta D.A., Fry J.D., Richfield E.K. Heritability, correlations and in silico mapping of locomotor behavior and neurochemistry in inbred strains of mice. Genes, Brain, and Behavior 2005, 4(4):209-228.
37. Millan M.J., Seguin L., Gobert A., Cussac D., Brocco M. The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: A combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology (Berl) 2004, 174(3):341-357.
38. Nader M.A., Mach R.H. Self-administration of the dopamine D3 agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure. Psychopharmacology (Berl) 1996, 125(1):13-22.
39. Niimi K., Takahashi E., Itakura C. Age dependence of motor activity and sensitivity to dopamine receptor 1 agonist, SKF82958, of inbred AKR/J, BALB/c, C57BL/6J, SAMR1, and SAMP6 strains. Brain Research 2009, 1250:175-182.
40. Phillips T.J., Hen R., Crabbe J.C. Complications associated with genetic background effects in research using knockout mice. Psychopharmacology (Berl) 1999, 147(1):5-7.
41. Pugsley T.A., Davis M.D., Akunne H.C., MacKenzie R.G., Shih Y.H., Damsma G., Heffner T.G. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. Journal of Pharmacology and Experimental Therapeutics 1995, 275(3):1355-1366.
42. Ralph R.J., Caine S.B. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: Comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice. Journal of Pharmacology and Experimental Therapeutics 2005, 312(2):733-741.
43. Ralph R.J., Caine S.B. Effects of selective dopamine D1-like and D2-like agonists on prepulse inhibition of startle in inbred C3H/HeJ, SPRET/EiJ, and CAST/EiJ mice. Psychopharmacology (Berl) 2007, 191(3):731-739.
44. Ralph-Williams R.J., Lehmann-Masten V., Geyer M.A. Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology 2003, 28(1):108-118.
45. Ralph-Williams R.J., Lehmann-Masten V., Otero-Corchon V., Low M.J., Geyer M.A. Differential effects of direct and indirect dopamine agonists on prepulse inhibition: A study in D1 and D2 receptor knock-out mice. Journal of Neuroscience 2002, 22(21):9604-9611.
46. Roberts D.C., Koob G.F., Klonoff P., Fibiger H.C. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacology, Biochemistry and Behavior 1980, 12(5):781-787.
47. Self D.W., Stein L. The D1 agonists SKF 82958 and SKF 77434 are self-administered by rats. Brain Research 1992, 582(2):349-352.
48. Skrinskaya J.A., Nikulina E.M., Popova N.K. Role of genotype in brain dopamine metabolism and dopamine-dependent behavior of mice. Pharmacology, Biochemistry and Behavior 1992, 42(2):261-267.
49. Thomsen, M., & Caine, S. B. (submitted). Psychomotor stimulant effects of cocaine in rats and 15 mouse strains.
50. Thomsen M., Hall F.S., Uhl G.R., Caine S.B. Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. Journal of Neuroscience 2009, 29(4):1087-1092.
51. Tirelli E., Terry P. Biphasic locomotor effects of the dopamine D1 agonist SKF 38393 and their attenuation in non-habituated mice. Psychopharmacology (Berl) 1993, 110(1-2):69-75.
52. Tirelli E., Witkin J.M. Differential effects of direct and indirect dopamine agonists on the induction of gnawing in C57Bl/6J mice. Journal of Pharmacology and Experimental Therapeutics 1995, 273(1):7-15.
53. Usiello A., Baik J.H., Rouge-Pont F., Picetti R., Dierich A., LeMeur M., Borrelli E. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 2000, 408(6809):199-203.
54. van Eimeren T., Ballanger B., Pellecchia G., Miyasaki J.M., Lang A.E., Strafella A.P. Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: A trigger for pathological gambling in Parkinson's disease?. Neuropsychopharmacology 2009, 34(13):2758-2766.
55. Wang Y., Xu R., Sasaoka T., Tonegawa S., Kung M.P., Sankoorikal E.B. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. Journal of Neuroscience 2000, 20(22):8305-8314.
56. Weed M.R., Woolverton W.L. The reinforcing effects of dopamine D1 receptor agonists in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 1995, 275(3):1367-1374.
57. Wilmot C.A., Fico T.A., Vanderwende C., Spoerlein M.T. Dopamine autoreceptor agonists attenuate spontaneous motor activity but not spontaneous fighting in individually-housed mice. Pharmacology, Biochemistry and Behavior 1989, 33(2):387-391.
58. Witkin J.M., Dijkstra D., Levant B., Akunne H.C., Zapata A., Peters S., Gasior M. Protection against cocaine toxicity in mice by the dopamine D3/D2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol[(+)-PD128,907]. Journal of Pharmacology and Experimental Therapeutics 2004, 308(3):957-964.
59. Woolverton W.L., Goldberg L.I., Ginos J.Z. Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 1984, 230(3):678-683.